Anne Zhuang, MD
Dermatology · Mill Valley, CANPI 1710277926
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 97 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 30.8% of the total. Reporting peaked in 2019 at $656 and has fallen 68.9% since, to $204 in 2025. That places this record below the midpoint for dermatology clinicians in CA, where the typical reported total is $1,655.
Across 97 payments — averaging $22.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$672
- Lilly USA, LLC$267
- Merz North America, Inc.$188
- Johnson & Johnson$163
- Galderma Laboratories, L.p.$142
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$139
- plus $608 from 13 others
What the payments were for
- Food & beverage$2,16199%
- Education$171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 37 | $672 |
| Lilly USA, LLC | 10 | $267 |
| Merz North America, Inc. | 9 | $188 |
| Johnson & Johnson | 9 | $163 |
| Galderma Laboratories, L.p. | 2 | $142 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 6 | $139 |
| Pfizer | 4 | $102 |
| Sientra, Inc. | 1 | $69 |
| Sun Pharmaceutical Industries Inc. | 3 | $61 |
| Botanix SB Inc | 3 | $57 |
| VYNE Pharmaceuticals Inc. | 2 | $54 |
| Smith+Nephew | 2 | $52 |
| Regeneron Healthcare Solutions, Inc. | 2 | $50 |
| E.r. Squibb & Sons, L.L.C. | 2 | $41 |
| Biofrontera Inc. | 1 | $29 |
| Dermavant Sciences, Inc. | 1 | $24 |
| Novartis | 1 | $24 |
| Dermira, Inc. | 1 | $23 |
| Amgen | 1 | $23 |
How this compares
$2,178 in reported general payments places this provider in the 50th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Hyclate | 132 | $934 |
| Mupirocin | 61 | $564 |
| Doxycycline Monohydrate | 21 | $241 |
| Cephalexin | 32 | $139 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 27 | $71 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Mill Valley
- Paul YamauchiSanta Monica$2.9M
- Jennifer SoungSanta Ana$2.8M
- Robert GreenbergLivermore$2.6M
- Neal BhatiaSan Diego$2.5M
- April ArmstrongLos Angeles$2.3M
- Jeffrey CrowleyBakersfield$2.1M
- Jashin WuCorona$2M
- Raja SivamaniSacramento$1.9M
- Tien NguyenFountain Valley$1.2M
- Tina BhutaniSan Francisco$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.